Navigation Links
Avantium Appoints Gunnar Staaf as CEO Pharma
Date:12/16/2009

AMSTERDAM, December 16 /PRNewswire/ -- Today, Avantium announced the appointment of Gunnar Staaf as Chief Executive Officer of its pharmaceutical business. Gunnar Staaf previously worked at Serentis Ltd, Astellas Pharma, Novartis and Eli Lilly & Company, in a range of commercial and executive positions. The appointment is an important step in Avantium's plan to spin-out its pharmaceutical business. The company intends to create a stand-alone pharmaceutical company based on its offering of proprietary crystallization services and systems to customers in the pharmaceutical and biotechnology sector as well as the development of improved forms of existing drugs. After the spin-out of its pharmaceutical business, Avantium will focus on its cleantech and chemicals activities, including its Furanics bioplastics and biofuels program and offering of high-throughput catalysis services & systems.

Tom van Aken, CEO of Avantium, commented: "With his background in the pharmaceutical industry and wealth of commercial experience, Gunnar is a tremendous addition to our company. The appointment of Gunnar is an important step towards a focused pharmaceutical company. Under Gunnar's leadership we believe that our Pharma business will accelerate the development of improved drug forms, and will further strengthen our position as a leading solid-state research services & systems provider."

Upon his appointment Gunnar Staaf commented: "I am pleased to join Avantium at this exciting stage. The company has an excellent technological position and expertise in crystallization research and is a leading provider of services & systems in this area. The technology forms a strong basis for the development of novel forms and formulations of existing drugs. I am convinced that we have all the ingredients to become a dedicated and successful pharmaceutical company."

About Avantium

Avantium is a leading technology company in the area of advanced high-throughput R&D operating in the energy, chemicals and pharmaceutical industries. The company develops products and processes in the area of biofuels, bio-based chemicals and novel crystal forms of existing drugs by applying its proprietary, high-throughput R&D technology.

Avantium has demonstrated the potential of this technology by providing R&D services and tools to more than 70 companies worldwide. Avantium's customer base includes many of the world's largest energy, chemicals and pharmaceutical companies, such as BP, Shell, Sasol, Pfizer and GSK. Avantium has more than 100 employees; its offices and head quarters are based in Amsterdam, The Netherlands.

For more information

Please visit our website http://www.avantium.com

SOURCE Avantium


'/>"/>
SOURCE Avantium
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors
2. Millstone Medical Outsourcing Appoints New Leadership of Memphis Facility
3. Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer
4. Jazz Pharmaceuticals Appoints Kathryn Falberg as Chief Financial Officer
5. Patient Safety Technologies, Inc. Appoints Marc L. Rose, CPA (PA), Chief Financial Officer
6. NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
7. Encorium Group, Inc. Appoints Sari Laitinen to Board of Directors
8. Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing
9. NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates
10. Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board of Directors
11. Company Appoints New SVP, Marketing for PBM Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market by Manufacturers, ... and analysed the potential of Global Effective Microorganisms (EM) Market ... growth factors. The report identifies and analyses the emerging trends ... market. ... and Figures, 6 Major Company Profiles, spread across 124 pages ...
(Date:4/19/2017)... LONDON , April 19, 2017 ... to stimulate an immune response in pets such ... vaccine products are of various types such as ... Vaccines, Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. ... such as virus or bacteria, which have been ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-naïve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
Breaking Medicine Technology:
(Date:4/26/2017)... Aviv, Israel (PRWEB) , ... April 26, 2017 , ... ... today announced a new partnership with Med-e-Mass , the largest Electronic Medical Records ... enable Med-e-Mass to link care plan incentives to a patient’s remote health progress, empowering ...
(Date:4/26/2017)... ... ... Miami native and local periodontist Dr. John Paul Gallardo is ... in 1991 that this journey would have taken me into so many learning experiences ... Gallardo has pioneered implant dentistry innovation, evolving into an internationally recognized leader in the ...
(Date:4/26/2017)... (PRWEB) , ... April 26, ... ... which provides an agile ecosystem and domain expertise for sponsors and CROs ... randomization and trial supply management (RTSM) software platform. Bioclinica AGILE RTSM ...
(Date:4/25/2017)... KY (PRWEB) , ... April 25, 2017 , ... ... announce they have signed an agreement to be the preferred physical therapy provider ... injuries and returning them to Derby City CrossFit as quickly and effectively as ...
(Date:4/25/2017)... ... April 25, 2017 , ... A recent report from ... performance for the 2015-16 school year across Wisconsin’s public schools, charter schools, and ... important patterns in student test score performance, the report’s limited analyses fail to ...
Breaking Medicine News(10 mins):